Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: [¹⁸F]-fluorodeoxyglucose positron emission tomography computed tomography of LAPC4-CR castration-resistant prostate cancer xenograft mod in soft tissue compartments
Other Titles: [(18)F]-fluorodeoxyglucose positron emission tomography computed tomography of LAPC4-CR castration-resistant prostate cancer xenograft mod in soft tissue compartments
Author: McCall, K.C.
Cheng, S.C.
Huang, Y.
Kohf, N.E.
Tupper, T.
Van den Abbeele, A.D.
Zukotynski, K.A.
Sweeney, C.J.
Citation: Translational Oncology, 2015; 8(3):147-153
Publisher: Elsevier
Issue Date: 2015
ISSN: 1944-7124
Statement of
Keisha C. McCall, Su-Chun Cheng, Ying Huang, Nancy E. Kohl, Tanya Tupper, Annick D. Van den Abbeele, Katherine A. Zukotynsk, and Christopher J. Sweeney
Abstract: Preclinical xenograftmodels have contributed to advancing our understanding of themolecular basis of prostate cancer and to the development of targeted therapy.However, traditional preclinical in vivo techniques using caliper measurements and survival analysis evaluate the macroscopic tumor behavior, whereas tissue sampling disrupts the microenvironment and cannot be used for longitudinal studies in the same animal. Herein,we present an in vivo study of [¹⁸F]-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) designed to evaluate the metabolism within the microenvironment of LAPC4-CR, a unique murine model of castration-resistant prostate cancer. Mice bearing LAPC4-CR subcutaneous tumors were administered [18F]-FDG via intravenous injection. After a 60-minute distribution phase, themice were imaged on a PET/CT scanner with submillimeter resolution; and the fused PET/CT images were analyzed to evaluate tumor size, location, and metabolismacross the cohort ofmice. The xenograft tumors showed [¹⁸F]-FDG uptake that was independent of tumor size and was significantly greater than uptake in skeletal muscle and liver in mice (Wilcoxon signedrank P values of .0002 and .0002, respectively). [¹⁸F]-FDG metabolism of the LAPC4-CR tumors was 2.1 ± 0.8 ID/cm³*wt, with tumor to muscle ratio of 7.4 ± 4.7 and tumor to liver background ratio of 6.7 ± 2.3. Noninvasive molecular imaging techniques such as PET/CT can be used to probe the microenvironment of tumors in vivo. This study showed that [18F]- FDG-PET/CT could be used to image and assess glucose metabolism of LAPC4-CR xenografts in vivo. Further work can investigate the use of PET/CT to quantify the metabolic response of LAPC4-CR to novel agents and combination therapies using soft tissue and possibly bone compartment xenograft models.
Rights: © 2015 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article under the CC BY-NC-ND license
DOI: 10.1016/j.tranon.2015.03.004
Appears in Collections:Aurora harvest 7
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_103042.pdfPublished version1.05 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.